9,083 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Kane Investment Management Inc.

Kane Investment Management Inc. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 9,083 shares of the company's stock, valued at approximately $781,000.

Several other large investors have also recently bought and sold shares of the stock. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Albion Financial Group UT grew its position in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after acquiring an additional 278 shares during the period. Sound Income Strategies LLC raised its stake in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after acquiring an additional 243 shares in the last quarter. Hager Investment Management Services LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $46,000. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $47,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NVO. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research report on Tuesday. They set an "underperform" rating on the stock. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Tuesday. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Trading Down 7.8 %

Shares of Novo Nordisk A/S stock traded down $4.89 during trading hours on Friday, hitting $57.99. The company's stock had a trading volume of 32,192,935 shares, compared to its average volume of 5,963,203. Novo Nordisk A/S has a 12 month low of $57.28 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market capitalization of $260.23 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The stock has a 50 day moving average of $76.03 and a 200 day moving average of $92.13.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.